Diabetes drug fails in study

Glaxo, Tolerx diabetes drug fails in study

Tolerx Inc. and GlaxoSmithKline PLC said Friday their potential diabetes drug failed to meet its goal in a late-stage study.

The companies are studying otelixizumab as a potential treatment for patients with Type 1 diabetes. In Type 1 diabetes, the autoimmune system destroys insulin producing cells, making it necessary for patients to receive insulin boosts. The condition is fatal if not treated with insulin.
Type 2 diabetes is more common and involves the body not being able to properly use the insulin it produces.

The companies have suspended a similar late-stage study on the drug, pending review of the failed study.

"While we are disappointed in the DEFEND-1 (study) results of otelixizumab, we remain committed to the development and commercialization of the candidates in our pipeline, each of which has a distinct mechanism and target for correcting abnormal immune responses," said Douglas J. Ringler, president and CEO of Tolerx, in a statement.

Tolerx is a privately held biotechnology company based in Cambridge, Mass.

http://www.businessweek.com/ap/financialnews/D9LT6ONG0.htm

http://www.depsyl.com/

http://back2basicnutrition.com/

http://bionutritionalresearch.olhblogspace.com/